Leo Seman

2.6k total citations
43 papers, 2.1k citations indexed

About

Leo Seman is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Leo Seman has authored 43 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Endocrinology, Diabetes and Metabolism, 23 papers in Surgery and 13 papers in Molecular Biology. Recurrent topics in Leo Seman's work include Diabetes Treatment and Management (23 papers), Lipoproteins and Cardiovascular Health (15 papers) and Diabetes Management and Research (11 papers). Leo Seman is often cited by papers focused on Diabetes Treatment and Management (23 papers), Lipoproteins and Cardiovascular Health (15 papers) and Diabetes Management and Research (11 papers). Leo Seman collaborates with scholars based in United States, Germany and United Kingdom. Leo Seman's co-authors include Sabine Pinnetti, Hans J. Woerle, Ernst J. Schaefer, Judith McNamara, Stefan Hantel, Sreeraj Macha, Elke Seewaldt-Becker, Timothy D. Tayler, Tim Heise and Joel J. Rubenstein and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Biochemistry.

In The Last Decade

Leo Seman

42 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leo Seman United States	25	1.5k	1.3k	681	272	259	43	2.1k
Elda Favari Italy	30	785 0.5×	1.4k 1.1×	664 1.0×	449 1.7×	543 2.1×	73	2.5k
Amy O. Johnson‐Levonas United States	28	801 0.5×	1.3k 1.0×	349 0.5×	344 1.3×	416 1.6×	89	2.4k
Amrith Rodrigues United States	7	1.2k 0.8×	1.3k 1.0×	424 0.6×	527 1.9×	418 1.6×	10	2.3k
Michel Komajda France	13	1.7k 1.2×	1.7k 1.3×	830 1.2×	1.0k 3.8×	459 1.8×	25	3.5k
Kashif Jafri United States	10	862 0.6×	968 0.8×	308 0.5×	374 1.4×	300 1.2×	13	1.9k
Núria Plana Spain	29	859 0.6×	1.4k 1.1×	726 1.1×	689 2.5×	461 1.8×	161	2.9k
Mary Jane Geiger United States	20	542 0.4×	748 0.6×	452 0.7×	552 2.0×	237 0.9×	31	2.5k
Min‐Ji Charng Taiwan	16	522 0.4×	883 0.7×	486 0.7×	582 2.1×	334 1.3×	40	2.3k
Katsunori Ikewaki Japan	33	1.5k 1.0×	2.1k 1.6×	717 1.1×	748 2.8×	793 3.1×	119	3.4k
Teik Chye Ooi Canada	27	1.0k 0.7×	1.2k 0.9×	361 0.5×	633 2.3×	309 1.2×	79	2.4k

Countries citing papers authored by Leo Seman

Since Specialization

Citations

This map shows the geographic impact of Leo Seman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leo Seman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leo Seman more than expected).

Fields of papers citing papers by Leo Seman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leo Seman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leo Seman. The network helps show where Leo Seman may publish in the future.

Co-authorship network of co-authors of Leo Seman

This figure shows the co-authorship network connecting the top 25 collaborators of Leo Seman. A scholar is included among the top collaborators of Leo Seman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leo Seman. Leo Seman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tesfaye, Helen, Luke E. Zabotka, Deborah J. Wexler, et al.. (2024). Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study. Journal of General Internal Medicine. 39(10). 1870–1879. 3 indexed citations

Crowe, Christopher L., Effie Kuti, B.M.K. Donato, et al.. (2023). Impact of pre‐existing type 2 diabetes with and without cardiovascular disease on patients with COVID ‐19. Diabetes Obesity and Metabolism. 25(9). 2464–2472.

Pellicori, Pierpaolo, David Fitchett, Mikhail Kosiborod, et al.. (2021). Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial. European Journal of Heart Failure. 23(7). 1085–1093. 28 indexed citations

Ferdinand, Keith C., et al.. (2018). EMPAGLIFLOZIN IMPROVES BLOOD PRESSURE AS WELL AS GLYCEMIC CONTROL IN AFRICAN AMERICAN PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION: A 24-WEEK RANDOMIZED CONTROLLED TRIAL. Journal of the American College of Cardiology. 71(11). A1750–A1750. 4 indexed citations

Chen, Linzhi, Arvid Jungnik, Yan‐Ping Mao, et al.. (2014). Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers. Xenobiotica. 45(6). 520–529. 24 indexed citations

Seman, Leo, Sreeraj Macha, Gerhard Nehmiz, et al.. (2013). Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects. Clinical Pharmacology in Drug Development. 2(2). 152–161. 111 indexed citations

Kanada, Shigeto, Kazuki Koiwai, Atsushi Taniguchi, et al.. (2013). Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation. 4(6). 613–617. 41 indexed citations

Riggs, Matthew M., Alexander Staab, Leo Seman, et al.. (2013). Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. The Journal of Clinical Pharmacology. 53(10). 1028–1038. 25 indexed citations

Heise, Tim, Leo Seman, Sreeraj Macha, et al.. (2013). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus. Diabetes Therapy. 4(2). 331–345. 99 indexed citations

10.

Sarashina, Akiko, Kazuki Koiwai, Leo Seman, et al.. (2012). Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects. Drug Metabolism and Pharmacokinetics. 28(3). 213–219. 73 indexed citations

11.

Macha, Sreeraj, et al.. (2012). Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 51(2). 132–140. 30 indexed citations

12.

Amakye, Dereck D., Wen Dai, Cynthia J. Girman, et al.. (2009). The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development. Clinical Pharmacology & Therapeutics. 86(1). 32–43. 41 indexed citations

13.

Schaefer, Ernst J., Judith McNamara, Bela F. Asztalos, et al.. (2005). Effects of Atorvastatin Versus Other Statins on Fasting and Postprandial C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Patients With Coronary Heart Disease Versus Control Subjects. The American Journal of Cardiology. 95(9). 1025–1032. 94 indexed citations

14.

Jenner, J L, Leo Seman, John S. Millar, et al.. (2005). The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. Metabolism. 54(3). 361–369. 48 indexed citations

15.

Schaefer, Ernst J., Judith McNamara, Timothy D. Tayler, et al.. (2003). Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. The American Journal of Cardiology. 93(1). 31–39. 117 indexed citations

16.

Seman, Leo, Carl de Luca, & J L Jenner. (2003). Isolation and Purification of Serum Lipoprotein (a) Using Lectin Affinity. Humana Press eBooks. 110. 131–136. 8 indexed citations

17.

Schaefer, Ernst J., Judith McNamara, Timothy D. Tayler, et al.. (2002). Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. The American Journal of Cardiology. 90(7). 689–696. 75 indexed citations

18.

Schaefer, Ernst J., et al.. (2001). Lipid lowering and weight reduction by home-delivered dietary modification in coronary heart disease patients taking statins. The American Journal of Cardiology. 87(8). 1000–1003. 4 indexed citations

19.

Rodríguez, Carmen, Leo Seman, José M. Ordovás, et al.. (1994). Lipoprotein(a) and coronary heart disease. Chemistry and Physics of Lipids. 67-68. 389–398. 19 indexed citations

20.

Zawadzki, Z, François Tercé, Leo Seman, et al.. (1988). The linkage with apolipoprotein (a) in lipoprotein (a) modifies the immunochemical and functional properties of apolipoprotein B. Biochemistry. 27(22). 8474–8481. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact